LeonaBio Inc (LONA)

Currency in USD
7.180
+0.180(+2.57%)
Real-time Data·
LONA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.0227.290
52 wk Range
3.23614.210
Key Statistics
Prev. Close
7.04
Open
7.2
Day's Range
7.022-7.29
52 wk Range
3.236-14.21
Volume
11.62K
Average Volume (3m)
33.27K
1-Year Change
101.1204%
Book Value / Share
5.25
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LONA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
18.000
Upside
+150.70%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

LeonaBio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 18.000
(+150.70% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citizens
Buy18.00+150.70%-UpgradeJul 30, 2026
Piper Sandler
Buy20.00+178.55%-New CoverageMay 27, 2026
Cantor Fitzgerald
Buy---MaintainApr 07, 2026
Mizuho
Buy16.00+122.84%10.00MaintainApr 06, 2026
Cantor Fitzgerald
Buy---New CoverageFeb 26, 2026

LeonaBio Inc SWOT Analysis


ALS Drug Promise
Athira Pharma's ATH-1105 shows potential in ALS treatment, with positive preclinical data and Phase 1 results driving future clinical plans
Financial Crossroads
Despite $37M cash reserves, Athira faces financial challenges. Market cap decline to $9.8M reflects investor caution amid strategic shifts
Strategic Pivot
Explore Athira's strategic review process and pursuit of partnerships to accelerate ATH-1105 development and enhance shareholder value
Market Sentiment
Analyst ratings hold at "Market Perform" without price targets, reflecting cautious optimism as Athira advances its focused ALS program
Read full SWOT analysis

Earnings

Latest Release
May 07, 2026
EPS / Forecast
-1.73 / -0.19
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

LONA Income Statement

Compare LONA to Peers and Sector

Metrics to compare
LONA
Peers
Sector
Relationship
P/E Ratio
−0.5x−9.1x−0.3x
PEG Ratio
−0.02−0.370.00
Price/Book
1.4x2.2x2.6x
Price / LTM Sales
-11.4x2.9x
Upside (Analyst Target)
155.7%84.2%56.7%
Fair Value Upside
Unlock1.0%10.2%Unlock

LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company’s lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer’s disease and Parkinson’s disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
564.58K6.01%3.97M
Other Institutional Investors
8.39M89.36%59.09M
Public Companies & Retail Investors
434.91K4.63%3.06M
Total
9.39M100.00%66.13M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Perceptive Advisors LLC20.04%1,882,37013,252
Perceptive Life Sciences Master Fund, Ltd.16.53%1,552,61410,930

People Also Watch

3.65
ACDC
+1.11%
2.66
RAY
-0.02%
6.25
JLHL
+8.70%
3.6020
TEF
-1.72%
4.82
SNAL
-1.63%

FAQ

What Is the LeonaBio (LONA) Stock Price Today?

The LeonaBio stock price today is 7.180 USD.

What Stock Exchange Does LeonaBio Trade On?

LeonaBio is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for LeonaBio?

The stock symbol for LeonaBio is "LONA."

What Is the LeonaBio Market Cap?

As of today, LeonaBio market cap is 67.450M USD.

What Is LeonaBio's Earnings Per Share (TTM)?

The LeonaBio EPS (TTM) is -16.063.

When Is the Next LeonaBio Earnings Date?

LeonaBio will release its next earnings report on Aug 17, 2026.

From a Technical Analysis Perspective, Is LONA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has LeonaBio Stock Split?

LeonaBio has split 1 times.

How Many Employees Does LeonaBio Have?

LeonaBio has 19 employees.

What is the current trading status of LeonaBio (LONA)?

As of Jul 30, 2026, LeonaBio (LONA) is trading at a price of 7.180 USD, with a previous close of 7.040 USD. The stock has fluctuated within a day range of 7.022 USD to 7.290 USD, while its 52-week range spans from 3.236 USD to 14.210 USD.

What Is LeonaBio (LONA) Price Target According to Analysts?

The average 12-month price target for LeonaBio is 18.000 USD, with a high estimate of 20 USD and a low estimate of 16 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +150.70% Upside potential.

What Is the LONA Premarket Price?

LONA's last pre-market stock price is 7.190 USD. The pre-market share volume is 480.000, and the stock has decreased by 0.150, or 2.130%.

What Is the LONA After Hours Price?

LONA's last after hours stock price is 7.150 USD, the stock has decreased by 0.110, or 1.560%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.